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Summary 
The CD21/CD19/TAPA-1  complex of B lymphocytes amplifies signal transduction through 
membrane immunoglobulin (mIg), recruits phosphatidylinositol 3-kinase (PI3-kinase), and induces 
homotypic cellular aggregation. The complex is unique among known membrane protein complexes 
of the immune system because its components represent different protein families, and can be 
expressed individually.  By constructing chimeric molecules replacing  the extraceUular, trans- 
membrane, and cytoplasmic regions of CD19 and CD21 with those of HLA-A2 and CD4, we 
have determined that CD19 and TAPA-1 interact through their extraceUular domains,  CD19 
and CD21 through their extracellular and transmembrane domains, and, in a separate complex, 
CD21 and CD35 through their extracellular domains. A chimeric form of CD19 that does not 
interact with CD21 or TAPA-1 was expressed in Daudi B lymphoblastoid cells and was shown 
to replicate two functions of wild-type CD19 contained within the complex: synergistic interaction 
with mIgM to increase intracellular free calcium and tyrosine phosphorylation and association 
with the p85 subunit of PI3-kinase after ligation of mlgM. The chimeric CD19 lacked the capacity 
of the wild-type CD19 to induce homotypic cellular aggregation, a function of the complex 
that can be ascribed to the TAPA-1 component. The CD21/CD19/TAPA-1 complex brings together 
independently functioning subunits to enable the B cell to respond to low concentrations of antigen. 
T 
he membrane proteins,  CD19, TAPA-1, CD21  (com- 
plement receptor type 2), and Leu-13 form a complex 
on human and murine B lymphocytes that has costimula- 
tory  activity  for  the  antigen  receptor,  membrane  IgM 
(mIgM)  1 (1, 2). Impairing the function of this complex in 
mice by administering antibody to CD21 (3, 4) or a soluble 
recombinant  form  of CD21  (5)  suppresses complement- 
mediated enhancement of antibody production to T-dependent 
antigens.  Cross-linking CD19 to mIgM on B cells lowers 
by two orders of magnitude the number of antigen receptors 
required for inducing DNA synthesis (6). The required coli- 
gation of the complex to the antigen receptor could occur 
physiologically with antigen that had activated complement 
to become coated with iC3b and C3dg and capable of inter- 
acting with CD21 (for a review, see reference 7), or by cells, 
such as foUicular dendritic and B cells, that may bear antigen 
1  Abbreviations used in this ~t,  er: [CaZ*]~,  intracellular free calcium; mlgM, 
membrane IgM; PI3-kinase, phosphotidylinositol 3-kinase; PLC, phos- 
pholipase C; WT, wild-type. 
on their plasma membranes and express CD23, another ligand 
for CD21 (8). The absence of CD21 from pre-B cells (9), 
which express CD19 (10) and TAPA-1 (11), suggests the ex- 
istence of an additional, as yet unknown, ligand for the com- 
plex which would most likely interact with the B ceU-specific 
component, CD19. 
The  biochemical  mechanism  by  which  the  complex 
costimulates is not understood, but may include several effects 
that have been reported for this membrane entity. Cross- 
linking any individual component of the complex with specific 
mAb induces cellular aggregation (12, 13), which may serve 
to amplify signaling by promoting adhesion of the responding 
B cell to APCs. Coligating CD21 (14-16), CD19 (1, 2, 17), 
or TAPA-1 (2) to suboptimal numbers of mIgM synergisti- 
cally enhances activation of phospholipase C (PLC). Cross- 
linking CD19 independently of mIgM also activates PI.C (18) 
by a mechanism distinct from that triggered by mlgM (17), 
and suppresses cellular activation by mIgM (18, 19), the latter 
effect being reminiscent of that of CD4 on T lymphocytes. 
CD19 has been shown to be a major substrate of a protein 
tyrosine kinase activated by mIgM, and tyrosine-phosphory- 
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(20),  an enzyme that is required for the cellular activating 
effects of certain receptor tyrosine kinases and the polyoma 
middle T  antigen/pp60 c-~r" complex. Thus, several biochem- 
ical pathways may be triggered by the CD21/CD19/TAPA- 
1/Leu-13 complex that  relate to its role in amplifying the 
response of B cells  to  antigen. 
These  multiple  biologic  effects  of  the  CD21/CD19/ 
TAPA-1/Leu-13 complex may reflect the discrete actions of 
individual components, each of which is a member of a dis- 
tinct protein family: CD21 of the regulators of complement 
activation family (7);  CD19 of the Ig superfamily (21, 22); 
and TAPA-1 of the tetraspan family of membrane proteins 
(23). Leu-13 has not been structurally characterized.  These 
components also have distinct patterns of cellular expression: 
CD21 is present on B, follicular dendritic, and some T  cells 
(7); CD19 is found only on B lymphocytes (10); TAPA-1 re- 
sides on most cells of hemopoietic lineage (11); and Leu-13 
can be expressed by B and T lymphocytes, endothelial cells, 
and placental trophoblasts (24-26). Thus, the complex differs 
from  certain  others  of the  immune  system,  such  as  the 
TCR-CD3 complex (27) and the mlg/Ig-ot,/3 complex (28, 
29), in that its components are derived from several protein 
families and may be expressed individually,  suggesting that 
each has a unique function in the complex. CD21 has a short, 
34-amino  acid  cytoplasmic  domain  and  an  extensive  ex- 
tracytoplasmic region in which are binding  sites  for iC3b, 
C3dg (30,  31),  and CD23  (8), consistent with  a role as a 
ligand binding  subunit  to link the complex to fluid phase 
reactions involving complement, and to cellular reactions as- 
sociated with the low affinity FceKII. Signaling by the com- 
plex is more likely to involve TAPA-1 and CD19. The former 
is unusual in having four, highly conserved, transmembrane 
domains, two of which contain acidic amino acids (23), and 
the latter has a long cytoplasmic domain of 243 amino acids 
(22) which already has been shown to participate in the recruit- 
ment of PI3-kinase (20).  However, it is not known which 
biologic functions of the complex require CD19, TAPA-1, 
or both. 
The present study defined the domain of CD19 that is re- 
quired for its interaction with TAPA-1. This permitted the 
construction  of a chimeric CD19 lacking this domain that 
would reside outside the CD21/CD19/TAPA-1 complex when 
expressed in B lymphoblastoid cells. This form of CD19 was 
compared on the same B cell line with wild-type CD19, which 
was associated with CD21 and TAPA-1, for synergistic en- 
hancement of B cell activation by mlgM, tyrosine phosphory- 
lation, and binding of PI-3 kinase after cross-linking of mlgM, 
and homotypic cellular  aggregation. 
Materials  and Methods 
Antibodies.  HB5 anti-CD21  (9) (American Type Culture Col- 
lection  [ATCC], Rockville, MD), YZ-1 anti-CD35  (32), HD37 
anti-CD19  (Dako Corp.,  Santa Barbara, CA), and B4 anti-CD19 
(Cappel Laboratories, Durham, NC), OKT4 anti-CD4  (ATCC), 
DA4.4 anti-IgM  (ATCC), 5A6 anti-TAPA-1 (11) (generous gift of 
Dr. Shoshanna Levy,  Stanford University, Stanford, CA), 4G10 an- 
tiphosphotyrosine  (UBI, Lake Placid, New York), and anti-p85 
(UBI) were used. Isotype-matched control murine antibodies were 
RPC5.4 IgG2A (ATCC), MOPC21 IgG1 (Cappel Laboratories), 
and IgG2b (Southern Biotechnology Associates, Birmingham, AL). 
Chimeric CDl9 Constructs.  To replace the extracytoplasmic re- 
gion of CD19 with that of CD4, and the transmembrane and cy- 
toplasmic regions with HLA-A2, a strategy  using PCR primers 
spanning the chimeric junctions was employed (see Table 1). PCR 
fragments joining the different domains bounded by unique restric- 
tion sites, BstEIII in the extracytoplasmic region of CD4 and ScaI, 
BsmI, and XhoI in the CD19 extracytoplasmic, transmembrane, 
and 3' untranslated regions, respectively, were generated. Chimeric 
cDNA constructs were cloned into the eukaryotic expression vector, 
pZipNeoSV (33) by means of flanking BamHI sites. In CD19AEc, 
which replaces the extracytoplasmic region of CD19 with that of 
CD4, primers CD19.1 and CD19.2 (Table 1) were used on a CD4 
template to generate a PCR fragment that contained CD4 sequence 
from the BstEII site to methionine  374 that was joined to CD19 
sequence from valine 276 of the transmembrane domain to the BsmI 
site. This fragment  was cloned into the BstEII site of CD4 and 
the BsmI site of CD19. CD19ACyt1 replaces the CD19 cytoplasmic 
region with that of HLA-A2 after proline 299, and CD19ACyt2 
after leucine 303. Using primers CD19.3 and CD19.4 or CD19.5 
and CD19.4 on a HLA-A2 cDNA template, two PCR fragments 
were generated containing  the BsmI site, CD19 transmembrane 
sequence to either proline 299 or leucine 303, HLA-A2 cytoplasmic 
sequence starting  at arginine 293 to the stop codon, and a XhoI 
site. These fragments were used to replace the BsmI/XhoI frag- 
ment of wild-type CD19. 
In CD19ATmCyt, which replaces both the transmembrane and 
cytoplasmic region of CD19 with that of HLA-A2, primers 19.6 
and 19.4 were used on a HLA template generating a fragment en- 
coding the extracytoplasmic region of CD19 from the ScaI site to 
lysine 275 joined to the entire HLA transmembrane and cytoplasmic 
regions  at  valine 269.  This  fragment  was used  to replace the 
ScaI/XhoI fragment in wild-type CD19 cDNA. In CD19AEcCyt, 
which  contains  only  the  CD19  transmembrane  region,  the 
BamHI/BsmI fragment of CD19AEc containing extracellular CD4 
was ligated by the BsmI site to the BsmI/BamHI fragment  of 
CD19ACyt2 containing HLA A2 cytoplasmic region. The resuking 
chimera contains CD4 extracelhilar, CD19  transmembrane,  and 
HLA cytoplasmic regions. 
CD21 Constructs.  To construct CD21 mutants  which replace 
the transmembrane and cytoplasmic regions of CD21 with HLA- 
A2 or delete the cytoplasmic region,  a PCR strategy  similar to 
that used with the CD19 chimeras was employed. A unique BglII 
site was generated in the extracytoplasmic region of CD21 using 
oligonucleotide-directed  mutagenesis  and  two-step  PCR  (34). 
Primers 21.1 and 21.2 were used on a CD21 cDNA template, and 
the PCR product used together with primer 21.3 on a CD21 tem- 
plate to create a silent C to T transition  in the third position of 
the serine 969 codon. Additional unique restriction  sites, EcoRV 
and BdI in CD21  were used. CD21  chimeras were cloned into 
the eukaryotic expression vector LXSN (35). In CD21ACyt, which 
replaces the cytoplasmic region of CD21 with HLA-A2, primers 
21.5 and 21.6 were used on HLA-A2 template  to create a PCK 
fragment  containing  the EcoRV site, CD21 transmembrane  se- 
quence to serine 978, HLA-A2 cytoplasmic sequence from arginine 
293, and the BclI site. This fragment replaced the EcoRV/BclI frag- 
ment of wild-type CD21. In CD21ATmCyt, which replaces the 
transmembrane and cytoplasmic regions of CD21 with HLA-A2, 
primers 21.7 and 21.6 were used on HLA-A2 template to create 
a fragment joining the CD21 extracellular region at proline 954 
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BclI sites. 
In CD21 Cyt minus, which deletes the cytoplasmic region of 
CD21, primers 21.1 and 21.4 were used on a CD21 template to 
introduce a stop codon after histidine 980 in the cytoplasmic re- 
gion of CD21. 
CD35 Constructs.  The CD35 chimeric construct and the CD35 
cytoplasmic deletion mutant were created by site-directed muta- 
genesis performed by the method of Kunkel (36). Constructs were 
cloned into the eukaryotic expression vector AprM8. In CD35 Cyt 
minus which deletes the cytoplasmic domain of CD35, oligonu- 
cleotide 35.1  was used to introduce a stop codon after histidine 
1957 in the cytoplasmic domain of CD35. This leaves only lysine 
and histidine in the CD35 cytoplasmic domain. In CD35ATmCyt, 
which replaces the transmembrane and cytoplasmic region of CD35 
with that of HLA-A2, oligo 35.2 was used to create a unique ApaLI 
site just 5' of the HLA transmembrane region. The ApaLI site near 
the CD35 extracellular/transmembrane junction was used to join 
the extracellular portion of CD35 at alanine 1928 to the transmem- 
brane/cytoplasmic region of HLA-A2 at glutamine 263. 
Cell Lines and Transfections.  K562 erythroleukemia cells and 
Daudi B lymphoblastoid cells were grown in RPMI  1640 sup- 
plemented with 10% bovine calf serum, 100 U/ml penicillin, 100 
/~g/ml streptomycin, and 2 mM L-glutamine.  K562 calls stably ex- 
pressing wild-type transfected CD19, CD21, or CD35 have been 
previously described (1). Mutant constructs were introduced into 
K562 cells by lipofection (1), and stable transfectants selected with 
400 #g/ml 0418 (Gibco BRL, Gaithersburg, MD) or when cotrans- 
fected with plasmid p141, which encodes hygromycin resistance, 
selected with 400 #g/ml hygromycin B (Calbiochem-Novabiochem 
Corp., La Jolla, CA). High expressing cells were sorted by fluores- 
cent flow cytometry. 
Daudi cells were transfected by electroporation in which 8  x 
106 cells were pelleted and brought up in 0.8 ml RPMI with 10% 
calf serum, and loaded into a 4-mm width electroporation cuvette 
together with 50 #g linearized DNA.  Cells were electroporated 
at 250 V, 960/~F using a Gene Pulser apparatus  (Bio-Rad Labora- 
tories, Richmond, CA). After 24 h of culture, cells were counted, 
diluted to 10  s, and cultured in media containing G418, 2 mg/ml, 
in 24-well plates.  Clones were isolated and stained for expression 
by fluorescent flow cytometry. 
Immunoprecipitation and Immunoblotting.  For analysis of copre- 
cipitating proteins, Dandi cells and K562 transfectants were sur- 
face labded with lZSI (New England Nuclear, Boston, MA) (37). 
Cells were lysed in a buffer containing 1% digitonin, and lysates 
immunoprecipitated  with 5/~g mAbs followed by protein A-trisacryl 
for isotypes IgG2a and IgG2b, or rabbit IgG anti-mouse Ig bound 
to Sepharose for IgG1 (1). Proteins were resolved on 5-20% SDS- 
polyacrylamide gradient gels and detected with autoradiography. 
To assess tyrosine phosphorylation and association  with the p85 
subunit of PI3-kinase,  Daudi ceils were stimulated with F(ab')z 
goat anti-human IgM for 5 min at room temperature, pelleted, 
and lysed in buffer containing 1% NP-40 and phosphatase and pro- 
tease inhibitors (20). Lysates were precipitated with OKT4 anti- 
CD4 or HD37 anti-CD19 followed by protein A-trisacryl beads 
or rabbit anti-mouse Ig bound to Sepharose, respectively. Proteins 
were resolved on 7.5% SDS-PAGE slab gels, transferred to nitrocel- 
hlose, and probed with l~I-labeled 4G10 antiphosphotyrosine an- 
tibody. The blots were reprobed with anti-p85 followed by detec- 
tion by enhanced chemiluminescence (ECL) (Amersham,  Arlington 
Heights, IL). 
Analysis  of [Ca2+li and  Homotypic  Aggregation  of  Daudi 
Cells.  Daudi transfectants loaded with indo-1 were preincubated 
with appropriate mAbs for 15 min at room temperature, washed, 
and the bound mAbs cross-linked  with F(ab')z goat anti-mouse 
Ig in the presence  of DMSO alone or containing 75 nM PMA. 
Table  1.  Oligonucleotides used in preparing CD21,  CDI9, and CD35 constructs 
Name  5'-Y Sequence 
19.1 
19.2 
19.3 
19.4 
19.5 
19.6 
21.1 
21.2 
21.3 
21.4 
21.5 
21.6 
21.7 
35.1 
35.2 
GCGTCTAGAGGTTACCCAGGACCCTAAGCTC 
GCGGAATTCGAATGCCCACAAGGGAACACAGGCAGAAGATCAGA 
TAAGCCAAAGTCACAGCTGAGCCATTGGCTGCACCGGGGTGGA 
GCGTCTAGAGGCATTCTTCATCTTCAAAGGAGGAAGAGCTCAGATAGA 
GCGGAATTCCTCGAGTCACACTTTACAAGCTGTGAG 
GCGTCTAGAGGCATTGTTCATCTTCAAAGAGCCCTGGTCCTGAGG 
AGGAAGAGCTCAGATAGA 
GCGTCTAGACCAGTACTATGGCACTGGCTGCTGAGGACTGGTGGCTGG 
AAGGTGGGCATCATTGCTGGCCTG 
TGCAGATCTCGTTCACTTGCTCCTGTC 
TGAATCGATAGCAGTTTCTTTCTAATC 
GTTCACGTGTGGAGCTAG 
CAGTGATCAGTGTTTTGATATCACGTA 
CGTGATATCAAGGAGGAAGAGCTCAGAT 
TTCTGATCACACTTTACAAGCTGT 
TGCAGATCTCGTTCACTTGCTCCTACCATCCCCATCGTGGGC 
ATAATTCTAAAGCACTGAGAAGGCAATAATGCA 
CTGGGATGGGAGCCGTGTGCACAGTCCACCGTCCCC 
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flow cytometry (17). 
Daudi cell  transfectants  were  suspended  in RPM110% calf  serum 
at 107/ml. The mAbs, 5A6 anti-TAPA-1, HD37 anti-CD19, and 
OKT4 anti-CD4, were  diluted in Hanks' buffered  saline with 20 
mM EDTA  and 0.1% BSA. In a 96-well  flat bottomed  plate (Costar 
Corp., Cambridge, MA), 0.1 ml of antibody dilution was added 
to 0.1 ml of cells and the cells incubated at 37~  for 45 min after 
which photomicrographs of representative  fields were taken. 
Results 
Domains of CDI9 that Mediate Association with TAPA-I and 
CD21.  To determine which regions of CD19 mediate the 
association of this protein with TAPA-1 and CD21, we pre- 
pared constructs encoding chimeric forms of CD19 in which 
the extracellular, transmembrane, and cytoplasmic regions had 
been replaced with the corresponding regions of CD4 and 
HLA A2 (Fig. 1).  Chimeric constructs and deletion mu- 
tants encoding altered forms of CD21 were also prepared to 
CD19 Constructs 
Ec (275)  Tm (24) 
CD4 Ec {374) 
[ 
CD4 Ec (374) 
Cyt(243) 
CD19AEcCyt 
HLA Cyt (33) 
T~CYl  (33)  CD19ACyt 1 
J  .~="LLA  C~ (33) co193c~ 2 
Tm (28) 
[:', ;,~.  I===~  CD19ATmCyt 
HLA TmCyt  (53) 
CD19 WT 
DD19AEc 
CD21 Constructs 
//  L2  '  l  Cyt (34) 
CD21 WT 
Ec (1005}  T 
I  //  I  ' .................  cD2, o  
HLA Cyt (33} 
[--~  J  I  3  CD21 Cyt minus 
I  /  ~  ......................  CD21ATmCyt 
HLA TmCyi (57) 
CD35 Constructs 
i  //  !  I  ,  oo s*  
Ec  (1930)  m (25  C~ (43) 
1  Y  I  I  ]  CD35Cyt  minus 
I  Y  ~  .......................  CD35AtmCyl 
HLA TmCyl {61) 
Figure 1.  Diagram  ofwLld-type (WT) CD19, CD21, CD35, and the 
mutant constructs in which the extracellular  (Ec), transmembrane  (Tin), 
or cytoplasmic (Cyt) regions have been replaced with corresponding  seg- 
ments of HLA-A2  and CD4, or the cytoplasmic  regions  have  been deleted 
(Cyt minus). The shaded portions represent  chimeric  substitutions and the 
numbers in parentheses represent the number of amino acids in each do- 
main. 
confirm the results obtained with the CD19 constructs (Fig. 
1). Wild-type and mutated constructs were stably transf~cted 
into K562 erythroleukemia cells which constitutively express 
TAPA-1, and incorporation of the membrane proteins  into 
complexes was assessed  by analyzing immunoprecipitates ob- 
tained  with  antibodies  to  CD19,  CD4,  and  CD21  from 
digitonin lysates of nsI surface-labeled cells. Anti-TAPA-1 
could not be used for these studies because it does not coim- 
munoprecipitate  other components of the CD21/CD19/ 
TAPA-1/Leu-13 complex (2) (data not shown), which may 
reflect disruption of the complex by antibody or masking 
of its epitope by CD19. 
Immunoprecipitation with anti-CD19 of digitonin lysates 
of K562 cells that had been stably transfected with constructs 
encoding wild-type CD19  and CD21  recovered not only 
CD19, but also CD21,  TAPA-1, and Leu-13 (Fig. 2 A), as 
has been previously reported (1, 2). Digitonin lysates were 
prepared of K562 cells expressing wild-type CD21 and ei- 
ther of the chimeric CD19 constructs,  CD19AEc, in which 
the extracellular region of CD19 had been replaced with that 
of CD4, and CD19AEcCyt, which also had the cytoplasmic 
domain replaced  with that of  HLA-A2, leaving only the trans- 
membrane domain of CD19. Anti-CD4 immunoprecipitated 
the chimeric proteins at 95 and 65 kD, respectively, and Leu- 
13, but not CD21  or TAPA-1 (Fig. 2 A). The absence of 
an association of CD21 with CD19AEc and CD19AEcCyt 
was observed also when CD21 was primarily immunopre- 
cipitated from lysates of K562 cells expressing these chimeric 
forms of CD19 (Fig. 2 B), confirming the requirement for 
the extracellular region of CD19 for interaction  with both 
TAPA-1 and CD21. 
Because of ambiguity in the position of the transmem- 
brahe-cytoplasmic  junction  in  CD19,  we  prepared  two 
CD19/HLA-A2 chimeras: CD19ACytl, in which the cyto- 
plasmic domain after proline 299 was exchanged with that 
of HLA-A2, and CD19ACyt2, in which the replacement oc- 
curred after leucine 303 (Fig. 1). To assess the role of the 
transmembrane region of CD19,  a third construct, CD19- 
ATmCyt, replaced both the transmembrane and cytoplasmic 
regions of CD19 with those of HLA-A2 (Fig. 1). These were 
expressed in K562 cells and examined for association with 
TAPA-1 and CD21. TAPA-1 coimmunoprecipitated with each 
chimeric form of CD19, indicating that the extracellular re- 
gion is not only necessary but sufficient to mediate associa- 
tion of CD19 with TAPA-1 (Fig. 3 A). CD21 coimmuno- 
precipitated with the CD19ACytl and CD19ACyt2 mutants, 
but not with the CD19ATmCyt chimera. This requirement 
for the transmembrane region of CD19  for its association 
with CD21 was confirmed when immunoprecipitates  were 
obtained with anti-CD21  rather than with anti-CD19  (Fig. 
3 B). Thus, both the extraceUular  and transmembrane regions 
of CD19  appear to mediate the interaction of this protein 
with CD21. 
Further support for this conclusion was obtained by anal- 
ysis of chimeric forms of CD21  in which the cytoplasmic 
domain (CD21ACyt), or both the transmembrane and cyto- 
plasmic domains (CD21ATmCyt) were replaced with these 
regions from HLA-A2 (Fig. 1). A third construct, CD21 Cyt 
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main of  CD19 on its association  with CD21 and TAPA-1. 
(A) Digitonin lysates were prepared from 12SI-labeled 
K562 transfectants  expressing  CD21 WT together with 
CD19AEcCyt or CD19AEc. Specific  immunoprecipi- 
tares (+) of  CD19 were obtained  with HD37 anti-CD19, 
and of CD19AEcCyt and CD19AEc with OKT4 anti- 
CD4; nonspecific  immunoprecipitates  (-) were also ob- 
tained. The proteins were resolved on SDS-polyacryl- 
amide gds and detected by autoradiography. (B) Im- 
munoprecipitates were obtained with HB5 anti-CD21 
from replicate  digitonin lysates of the 12SI-labded  K562 
transfectants expressing  CD21 WT together with CD19 
WT, CD19AEcCyt, or CD19AEc. The proteins were 
resolved  on SDS-polyacryhmide  gds and detected  by au- 
toradiography. 
Figure 3.  Effect  of substituting the transmembrane or cytoplasmic domains of CD19 on its association with CD21 and TAPA-1. (.4) Digitonin 
lysates were prepared from 12SI-labded  K562 transfectants expressing CD21 WT together with CD19ACytl,  CD19ACyt2, or CD19ATmCyt, and 
from 12Sl-labded  Raji B lymphoblastoid cells which bear wild-type CD21 and CD19. Specific  immunoprecipitates (+) were obtained from wild-type 
CD19 and the CD19 chimeras with HD37 anti-CD19. Nonspecific  immunoprecipitates (-) were also obtained. The proteins were resolved  on SDS- 
polyacrylamide  gels and detected by autoradiography. (B) Immunoprecipitates were obtained with HB5 anti-CD21 from replicate digitonin lysates of 
12SI-labded K562 transfectants expressing CD21 WT together with CD19ACytl,  CD19ACyt2, or CD19ATmCyt, and from 12SI-labded Raji cells. 
The proteins were resolved on SDS-polyacrylamide  gels and detected by autoradiography. 
minus, deleted the cytoplasmic domain of CD21 (Fig. 1). Im- 
munoprecipitation  with  anti-CD21  from K562 cells trans- 
fected with wild-type CD19 and the CD21 constructs indi- 
cated that substitution or removal of the cytoplasmic region 
of CD21 did not alter the coprecipitation of wild-type CD19, 
whereas substitution of the cytoplasmic and transmembrane 
domain  abolished  this  association  (Fig.  4). 
Figure 4.  Effect  of substituting or deleting the transmembrane or cy- 
toplasmic regions of CD21 on its association  with CD19. Digitonin ly- 
sates were prepared from 12SI-labeled  K562 transfectants  expressing CD19 
WT together with CD21 WT, CD21ACyt, CD21ATmCyt, or CD21 
Cyt minus. Specific  immunoprecipitates  (+) were obtained  with HB5 anti- 
CD21. Nonspecific  (-) immunoprecipitates  were also obtained. The pro- 
teins were resolved  on SDS-polyacrylamide  gels and detected  by autoradi- 
ography. 
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Domains that Mediate the Association of CD21  and CD35. 
The CD21ATmCyt, CD21ACyt, and CD21 Cyt minus con- 
structs were coexpressed with wild-type CD35 in K562 cells 
to determine the regions mediating the CD21/CD35  com- 
plex (38). Immunoprecipitation with anti-CD35 from digi- 
tonin lysates of these cells recovered CD35  and each form 
of CD21  (Fig.  5),  indicating  that  the transmembrane  and 
cytoplasmic domains of CD21  are not required for interac- 
tion with  CD35.  Consistent  with  this  conclusion was  the 
observation that CD21 was coprecipitated with anti-CD35 
from lysates of K562  cells expressing wild-type  CD21  to- 
gether with wild-type CD35, CD35 in which the transmem- 
brahe and cytoplasmic domains had been replaced with those 
of HLA-A2, or CD35 in which the cytoplasmic region had 
been  deleted  (Figs.  1  and  6). 
Functions Mediated by CDIgAEc Independent of the CD21/ 
CD19/TAPA-1 Complex.  To determine which functions of 
CD19 on B cells were dependent on interactions with TAPA-1 
or CD21, we expressed the CD19AEc chimera, in which the 
extracellular domain had been replaced with  that  of CD4, 
in Daudi B lymphoblastoid cells which also express constit- 
utively wild-type  CD19,  TAPA-1,  and  CD2L  Daudi  ceils 
do  not  express  Leu-13  and  any  functions  mediated  by Figure  5.  Effect  of substitut- 
ing the transmembrane or cyto- 
phsmic regions of CD21 on its as- 
sociation with CD35. Digitonin 
lysates were prepared from 12sI- 
hbeled K562 transfectants expres- 
sing CD35  WT  together  with 
CD21ACyt  or  CD21ATmCyt. 
Specific immuuoprecipitates (+) 
were obtained with  Y7_,1 anti- 
CD35. Nonspecific immunopre- 
cipitates (-) were also obtained. 
The proteins  were  resolved on 
SDS-polyacrylamide  gels and de- 
tected by autoradiography. 
Figure  6.  Effect  of substituting or deleting the transmembrane or cy- 
toplasmic region of CD35 on its association with CD21. Digitonin  ly- 
sates were prepared from lzsI-labeled  K562 transfectants expressing CD21 
WT together  with  CD35ATmCyt  or CD35  Cyt minus.  Specific im- 
munoprecipitates (+) were obtained with YZ-1 anti-CD35.  Nonspecific 
immunoprecipitates (-) were also obtained. The proteins were resolved 
on SDS-polyacrylamide  gels and detected by autoradiograpby. 
CD19AEc in this cell line would be independent  of Leu-13. 
The amount of the chimeric protein expressed by these cells 
was  approximately  one  half that  of wild-type  CD19.  Im- 
munoprecipitates  obtained with anti-CD4 from transfected 
Daudi cells contained only the CD19AEc chimera, whereas 
anti-CD19  recovered wild-type CD19,  CD21,  and TAPA-1 
from replicate  samples  of lysates  (Fig.  7). 
The capacity of the CD19AEc  chimera synergistically to 
increase  [Ca2+]i  when  coligated with  suboptimal  numbers 
of mlgM on transfected Daudi cells was compared with that 
of wild-type CD19, which is contained within the complex, 
Witl~ut PMA  W'~ PMA 
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IgM  IgM 
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1|  ~  eo  i~o  ~ao  2~o  1oo  ~  eo  ~2o  1;o  240 
...,$(30'  500 
'~  100  ............ 
..~ 4000  60  ,  ,  40  40  4~Ow 
CD19AEC  CD19Z~-C 
￿9  _ 
1|  .  1/0  Ii0  240  I~  .  ~i0  li0  240 
TAPA-1  TAPA-1 
'  21W~ 
i  ....  1  lOGO ~  ~  120  110  240  100  1  60  120  110  240 
￿9 ~  (~) 
Figure  8.  Synergistic increases in [Ca2+]i in Daudi  transfectants in- 
duced by cross-linking mlgM, CD19, CD19AEc, or TAPA-1 alone or to- 
gether in the absence or presence of PMA. The Daudi transfectants that 
had been loaded with indo-1 were preincubated with appropriate mAbs 
which were cross-linked  by the addition (arrow) of F(ab')2 goat anti-mouse 
Ig. Changes in fluorescence  of indo-1 were monitored by flow cytometry. 
The top panels show the response of cells that had been incubated with 
optimal (2/zg/ml) (@) and suboptimal (0.004 #g/ml) (O) Fab DA4.4 
anti-IgM. The other panels depict the results of cells that had been acti- 
vated by cross-linking antibodies to CD19, to CD4 to ligate CD19AEc, 
and to TAPA-1 either alone (O) or together with suboptimal Fab DA4.4 
anti-lgM (O). The concentrations of  anti-CD19, anti-CD4, and anti-TAPA-1 
mAbs were adjusted to yield equivalent binding of each, and all reactions 
were carried out in the absence or presence of 75 nM PMA. 
Figure  7.  Analysis  of membrane proteins coimmunoprecipitating with 
wild-type CD19 and recombinant CD19AEc from transfected  Daudi cells. 
Digitonin lysates were prepared from 12SI-labded  Daudi transfectants ex- 
pressing CD19AEc, and from 12SI-labeled  wild-type Daudi cells. Specific 
immunoprecipitates (+) were obtained of wild-type CD19 with HD37 
anti-CD19,  and of CD19AEc with  OKT4 anti-CD4;  nonspecific im- 
munoprecipitates (-) were also obtained. The proteins were resolved on 
SDS-polyacrylamide gels and detected by autoradiography. 
or with that of TAPA-1. The function of TAPA-1 could also 
be assessed independently of the complex by the use of anti- 
TAPA-1 because the mAb interacts  only with TAPA-1  that 
is flee of the complex.  In contrast to the increase in [CaZ+]i 
seen after cross-linking saturating amounts of anti-IgM,  no 
increase in  [Ca2+]i was induced  by addition  of F(ab')2 goat 
anti-mouse  Ig to cells bearing  either  suboptimal  amounts 
of anti-IgM,  or to cells bearing equivalent amounts of anti- 
1412  Functional  Dissection of the CD21/CD19/TAPA-1/Leu13 Complex CD19,  anti-TAPA-1 or anti-CD4  (Fig. 8).  Coligating the 
CD19AEc chimera, TAPA-1, or wild-type CD19 to mlgM 
induced similar synergistic increases in [Ca2+]i (Fig. 8). In 
nontransfected Daudi cells, anti-CD4 alone or in combination 
with suboptimal concentrations of anti-IgM did not alter 
[Ca2+]i (data not shown). In the presence of PMA, the syn- 
ergistic increase in [Ca  2§ ]i seen after coligating the CD19AEc 
chimera with mlgM was maintained,  as was that obtained 
with the coligation of  wild-type CD19 with IgM, as has been 
previously reported (17) (Fig. 8). PMA abolished the [Ca2+]i 
increase seen when TAPA-1 was coligated to mlgM, or when 
cells were stimulated with saturating concentrations of anti- 
IgM  alone  (Fig. 8).  Therefore,  two  components of the 
CD21/CD19/TAPA-1 complex, CD19 and TAPA-1, can in- 
teract with mlgM synergistically to increase [Ca  2+ ]i, but the 
CD19 component is responsible for the capacity of the com- 
plex to induce resistance to inhibition of PMA. 
To determine whether other components of the complex 
are required for mlgM to induce the tyrosine phosphoryla- 
tion of CD19 and association with the p85 subunit of PI3- 
kinase,  we immunoprecipitated wild-type CD19  and the 
CD19AEc chimera from lysates of  transfected Daudi cells that 
had been treated with buffer or anti-IgM. Selective immu- 
noprecipitation with monoclonal anti-CD19  and anti-CD4 
revealed that both forms were tyrosine phosphorylated to a 
similar extent (Fig. 9 A). Anti-CD4 did not recover tyrosine 
phosphorylated protein  from  nontransfected  Daudi  cells. 
Reprobing the same immunoblot with anti-p85 revealed the 
coimmunoprecipitation of this  subunit of PI3-kinase with 
both tyrosine-phosphorylated  CD19 and the CD19AEc chi- 
mera (Fig. 9 B), indicating that at least Y484 and Y515, which 
mediate binding to p85 (20), were tyrosine phosphorylated 
in the chimera. 
Homotypic aggregation  of Daudi  cells expressing  the 
CD19AEc  chimera was  assessed after treatment with in- 
cremental concentrations of mAbs to CD19,  TAPA-1, and 
CD4, respectively, in the presence of  EDTA, to exclude LFA- 
1-dependent effects. Replicate samples of cells were stained 
with fluoresceinated second antibody to quantitate the rela- 
tive  amounts of bound  antibodies.  Anti-CD19  and  anti- 
Figure 9.  Tyrosine  phosphorylation  and association  of CD19 with the 
p85 subunit of PI3-kinase. (A) Daudi  WT and transfectants  were  stimu- 
lated with F(ab')z goat anti-human  IgM (S), or treated  with buffer  alone 
(U). NP-40  lysates  were  immunoprecipitated  with  anti-CD4  or anti-CD19, 
proteins resolved  by SDS-PAGE,  transferred  to nitrocellulose,  and probed 
with l~I-labeled  4G10 antiphosphotyrosine  which  was detected  by auto- 
radiography. (/3)  The immunoblot  in (A) was reprobed  with anti-p85 fol- 
lowed by detection  with ECL. 
TAPA-1 each caused the cells to aggregate in a dose-dependent 
manner, whereas anti-CD4 had no effect (Fig. 10). There- 
fore, the capacity of CD19 to induce this cellular response 
is dependent on its association with other components of 
the complex,  most likely TAPA-1. 
Discussion 
A possible biologic role of the CD21/CD19/TAPA-1  com- 
plex is to enable the B cell to respond to low concentrations 
of  antigen, despite having low affinity  antigen receptors, during 
the primary immune response by amplifying or altering signal 
transduction through the antigen receptor. Several  biochem- 
ical responses mediated by the complex have  been described 
that may contribute to this process: enhanced cellular adhe- 
sive properties,  augmented activation  of PLC, and recruit- 
ment of PI3-kinase. Assessing the contribution of each re- 
sponse to the enhancement of B cell activation requires that 
each be individually elicited or suppressed. To accomplish this 
task, the complex must be physically  and functionally dissected. 
10 mutants of  CD19, CD21, and CD35 (Fig. 1) were con- 
structed and examined for their capacity to interact with other 
components of the complex. Substitution of either the trans- 
membrane or extracellular, but not the cytoplasmic, domains 
of either CD19 (Figs. 2 and 3) or CD21  (Fig. 4) abolished 
the coimmunopredpitation of these two proteins, confirming 
their direct  interaction  and suggesting that they associate 
through at least two sites. Precedent for a two-site mode of 
interaction  among  membrane  protein  complexes  is  the 
mlgM/Ig-oe/fl complex in which the transmembrane domains 
of the heterodimer form a sheath enclosing  the conserved 
polar amino acids of  the transmembrane region of  mlgM (39), 
and the ectodomains interact with the CH3 and CH4 regions 
of mlgM (40). However, CD19  and CD21 differ from the 
components of the mlgM complex and the TCR complex 
(41) in lacking many polar or any charged amino acids in 
their transmembrane domains,  and in being able to be ex- 
pressed independently. Site-directed mutagenesis of the trans- 
membrane domains of these proteins will be necessary to de- 
termine if their intramembranous interaction  is based on 
mechanisms  similar to those mediating the formation of  homo- 
and heterodimeric complexes by glycophorin A (42) and class 
II MHC (43) proteins, respectively, membrane proteins with 
transmembrane domains similarly lacking in polar or charged 
amino acids. The finding that CD21 could be lost selectively 
from the complex of CD19 and TAPA-1 (Fig. 2) confirms 
and extends an earlier finding that CD21  and TAPA-1 did 
not associate in K562 cells until CD19 was also expressed 
(1), and does not support a suggestion that CD21 and TAPA-1 
interact  directly (2). Thus, CD19 is essential for assembly 
of the CD21/CD19/TAPA-1 complex. 
The interaction of CD19 with TAPA-1 required only its 
extracytoplasmic region (Figs. 2 and 3).  We did not alter 
TAPA-1 to confirm the extracytoplasmic association of these 
two proteins, but this conclusion would be consistent with 
the inability  of the 5A6 anti-TAPA-1 mAb, whose epitope 
resides in the second extracellular loop of TAPA-1 (23), to 
coimmunoprecipitate  CD19, if it is assumed that the epitope 
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of CD21 with CD35 was also mediated by the extracyto- 
plasmic regions of these proteins (Figs.  5 and 6) which, if 
the sites in CD21 for CD19 and CD35 overlap, would ex- 
plain an earlier demonstration that CD21 did not associate 
simultaneously with both CD19 and CD35 (38). CD21 must 
be capable of efficiently capturing immune complexes from 
CD35 after C3b has been processed to iC3b and C3dg, and 
after which CD21 must associate with CD19 for the pur- 
pose of signal transduction. Mediating the association of CD21 
and CD35 through their extracelhlar domains may  be a means 
by which the binding of ligand regulates this interaction. 
There is also precedent in the immune system for interac- 
tion among membrane proteins being mediated solely by ex- 
tracellular  domains. Both the IL-2 (44,  45)  and IL-6 (46) 
receptors have ligand binding subunits that associate with 
signaling subunits through their extracellular  regions. The 
mode of interaction of Leu-13, for which a primary struc- 
ture has not been defined, is complex, but may involve TAPA-1 
and the transmembrane domain of CD19 (Fig.  2). In sum- 
mary, two of the three interaction domains of the CD21/ 
CD19/TAPA-1  complex  are  extracytoplasmic,  one  is  in- 
tramembraneous, and none is cytoplasmic (Fig.  11). 
The objective of these structural studies was to determine 
rules to guide the construction of a form of CD19 that would 
not interact with other components of the complex in a B 
lymphoblastoid  cell line (Fig. 7) and which would allow three 
questions to be posed: (a) was CD19 solely responsible for 
the capacity of the CD21/CD19/TAPA-1 complex to interact 
synergistically  with mlgM for increasing [Ca2+]i;  (b)  did 
CD19 need to be contained within the complex to be a sub- 
strate for a protein tyrosine kinase activated by mlgM; and 
was the homotypic  cellular aggregation induced by antibodies 
to CD19 (13) dependent on its association  with TAPA-I? 
The CD19AEC chimera replicated the capacity of the com- 
plex to cause amplified signaling with mlgM that was resis- 
tant to inhibition by PMA (Fig. 8). This evidence for CD19 
altering in a qualitative as well as quantitative manner the 
PMA-sensitive signaling process initiated by mlgM had been 
previously noted when crosslinking the complex to mlgM 
augmented activation of PLC without increasing the tyro- 
sine phosphorylation of PI.C% the mechanism of PLC acti- 
vation by mlgM alone (47). This effect of CD19AEC con- 
trasted with that of TAPA-1 which only enhanced the increase 
in [Ca  2+]i when cross-linked  to mlgM, but did not render 
the response resistant to PMA (Fig. 8). This differential effect 
may relate to the capacity of anti-CD19, but not anti-TAPA-1, 
to decrease the threshold of B cell proliferation when coligated 
with mlgM (6). 
The CD19AEC chimera was tyrosine phosphorylated and 
bound PI3-kinase in a manner that was quantitatively similar 
to wild-type CD19 contained within the complex (Fig. 9). 
This finding, when coupled with a previous suggestion that 
the tyrosine kinase activated by the mlg complex is physi- 
Figure  10.  Photomicrographs  of  transfected 
Daudi  cells  that  had  been  incubated with  in- 
cremental concentrations of anti-CD19 and anti- 
CD4,  which ligate the CD19AEc chimera, and 
anti-TAPA-1,  respectively. Replicate samples of cells 
incubated with identical concentrations of antibody 
were stained with fluoresce/hated goat anti-mouse 
Ig and analyzed by flow cytometry. The numbers 
in  parentheses  represent  the  mean  fluorescent 
channels  of the stained  cells. 
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Figure  11.  Scheme  depicting the domains mediating the interactions 
of the components of the CD21/CD19/TAPA-1 complex, and the func- 
tions of these components. 
cally limited to proximate substrates, suggests that the trans- 
membrane or cytoplasmic domain of CD19 is su~cient  to 
localize the protein to the appropriate membrane site for its 
phosphorylation  by the activated tyrosine kinase (48). 
The inability of the CD19AEC chimera to induce homo- 
typic cellular aggregation (Fig. 10) indicates that the capacity 
of the CD21/CD19/TAPA-1 complex to cause this response 
can be ascribed wholly to the TAPA-1 component.  This is 
consistent with earlier observations that anti-TAPA-1 causes 
the aggregation of hemopoietic cell lines that express TAPA-1 
but not CD19 (12), but the possibility that CD19 also had 
this function could not be excluded until the present study. 
The findings of distinct and separable functions of the in- 
dividual components of the CD21/CD19/TAPA-1 complex 
lead to a view of the complex as a mosaic comprised of subunits 
that had evolved independently. Thug CD19 may have evolved 
with the immune system, with its spedalized functions relating 
to amplifying signaling  through the antigen receptor.  TAPA-1 
has a general function among hemopoietic cells of promoting 
cellular adhesion, and may have been recruited to the com- 
plex because of the need for B ceils to adhere to APCs. CD21 
presumably was adapted from other C3-binding proteins to 
link the recognitive capabilities of the complement  system 
to the earliest phase of the humoral immune response when 
recognition  of antigen  is most tenuous. 
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